What are the drug interactions with non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiretroviral therapy?

1. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001. 344(13):984-996.

2. [Guideline] HIV guidelines DHHS. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. June 3 2021; Accessed: July 10 2021.

3. [Guideline] HIV Drug-Drug Interactions. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/overview. June 4 2021; Accessed: July 10 2021.

4. [Guideline] Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-non-nucleoside-reverse-transcriptase. June 3 2021; Accessed: July 10 2021.

5. clinicalinfo.hiv.gov. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-non-nucleoside-reverse-transcriptase. June 3 2021; Accessed: July 10 2021.

6. [Guideline] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Drug Interactions between protease inhibitors and other drugs. Department of Health and Human Services. Jun 3 2021. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-protease-inhibitors-and-other-drugs. Accessed: July 10 2021.

7. [Guideline] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Drug Interactions between integrase inhibitors and other drugs. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/interactions-between-integrase-inhibitors-and-non-nucleoside. June 4 2021; Accessed: July 10 2021.

8. HIV guidelines. clinicalinfo.hiv.gov. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/interactions-between-integrase-inhibitors-and-non-nucleoside. June 3 2021; Accessed: July 10 2021.

9. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009. 53(7):2852-2856:

10. [Guideline] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Drug Interactions between NRTIs and other drugs. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-nucleoside-reverse-transcriptase. June 3 2021; Accessed: July 10 2021.

11. [Guideline] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Drug Interactions between CCR5 antagonists and other drugs. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-ccr5-antagonist-and-other-drugs?view=full. June 3 2021; Accessed: July 10 2021.

12. clinicalinfo.hiv.gov. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-hiv-1-gp120-directed-attachment?view=full. June 3 2021; Accessed: July 10 2021.

13. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004. 48(6):2091-2096:

Shahab Qureshi, MD, FACP Attending Physician in General Internal Medicine, St Catharine's General Hospital; Associate Clinical Professor (Adjunct), McMaster University School of Medicine, Canada

Shahab Qureshi, MD, FACP is a member of the following medical societies: American College of Physicians, College of Physicians and Surgeons of Ontario, Ontario Medical Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.